These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27293539)

  • 21. Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009-2020.
    Hankosky ER; Schapiro D; Gunn KB; Lubelczyk EB; Mitroi J; Nelson DR
    Diabetes Ther; 2023 Jun; 14(6):967-975. PubMed ID: 37067668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients' empowerment, physicians' perceptions, and achievement of therapeutic goals in patients with type 1 and type 2 diabetes mellitus in Mexico.
    Lavalle-González FJ; Chiquete E
    Patient Prefer Adherence; 2016; 10():1349-57. PubMed ID: 27555751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries.
    van Mark G; Lanzinger S; Sziegoleit S; Putz FJ; Durmaz M; Borscheller M; Danne T; Seufert J; Holl RW; Bramlage P
    Adv Ther; 2019 Jul; 36(7):1628-1641. PubMed ID: 31119688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
    Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis.
    Cigrovski Berkovic M; Petrovski G; Grulovic N
    Acta Diabetol; 2016 Oct; 53(5):709-15. PubMed ID: 27098531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients' education, and its impact on care outcomes, resource consumption and working conditions: data from the International Diabetes Management Practices Study (IDMPS).
    Gagliardino JJ; Aschner P; Baik SH; Chan J; Chantelot JM; Ilkova H; Ramachandran A;
    Diabetes Metab; 2012 Apr; 38(2):128-34. PubMed ID: 22019715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study.
    Seufert J; Pfohl M; Borck A; Bramlage P; Siegmund T
    Diabetes Ther; 2021 Mar; 12(3):749-764. PubMed ID: 33544356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.
    Fonseca V; Davidson J; Home P; Snyder J; Jellinger P; Dyhr Toft A; Barnett A
    Curr Med Res Opin; 2010 Jul; 26(7):1621-8. PubMed ID: 20429817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.
    Hong EG; Min KW; Lim JS; Ahn KJ; Ahn CW; Yu JM; Kim HS; Kim HJ; Kim W; Kim DH; Jang HC
    Adv Ther; 2024 May; 41(5):1967-1982. PubMed ID: 38512540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS).
    Chan JC; Gagliardino JJ; Baik SH; Chantelot JM; Ferreira SR; Hancu N; Ilkova H; Ramachandran A; Aschner P;
    Diabetes Care; 2009 Feb; 32(2):227-33. PubMed ID: 19033410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of carbohydrate counting versus other forms of dietary advice in patients with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials.
    Builes-Montaño CE; Ortiz-Cano NA; Ramirez-Rincón A; Rojas-Henao NA
    J Hum Nutr Diet; 2022 Dec; 35(6):1030-1042. PubMed ID: 35436364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Characteristics, Glycemic Control, and Microvascular Complications Compared Between Young-Onset Type 1 and Type 2 Diabetes Patients at Siriraj Hospital - A Tertiary Referral Center.
    Preechasuk L; Tantasuwan S; Likitmaskul S; Santiprabhob J; Lertbannaphong O; Plengvidhya N; Tangjittipokin W; Nitiyanant W; Lertwattanarak R
    Diabetes Metab Syndr Obes; 2022; 15():1375-1387. PubMed ID: 35528720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study.
    Jin Y; Sun X; Zhao X; Zhu T
    Diabetes Ther; 2017 Jun; 8(3):611-621. PubMed ID: 28349442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One in Seven Insulin-Treated Patients in Developing Countries Reported Poor Persistence with Insulin Therapy: Real World Evidence from the Cross-Sectional International Diabetes Management Practices Study (IDMPS).
    Chan JCN; Gagliardino JJ; Ilkova H; Lavalle F; Ramachandran A; Mbanya JC; Shestakova M; Dessapt-Baradez C; Chantelot JM; Aschner P
    Adv Ther; 2021 Jun; 38(6):3281-3298. PubMed ID: 33978906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Adding Prandial Insulin to a Basal Based Regimen with Insulin Glargine in Type 2 Diabetic Patients.
    Khamseh ME; Abbasi Ranjbar Z; Banazadeh Z; Mirfeizi M; Mohammadbeiki M; Mozafari Z; Razazian K; Malek M
    Med J Islam Repub Iran; 2021; 35():177. PubMed ID: 35685198
    [No Abstract]   [Full Text] [Related]  

  • 37. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Madsen KS; Chi Y; Metzendorf MI; Richter B; Hemmingsen B
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008558. PubMed ID: 31794067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina.
    José GJ; Jorge E; Lujan F; Ivanna Q; Jean-Marc C
    Diabetes Res Clin Pract; 2019 Jul; 153():86-92. PubMed ID: 31102686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.